Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Cantor Fitzgerald
Deloitte
Citi
US Army
Covington

Generated: August 22, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,528,099

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,528,099
Title:Fusion proteins of collagen-binding domain and parathyroid hormone
Abstract: Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.
Inventor(s): Gensure; Robert C. (New York, NY), Sakon; Joshua (Fayetteville, AR), Matsushita; Osamu (Okayama, JP), Ponnapakkam; Tulasi (New York, NY)
Assignee: Ochsner Clinic Foundation (N/A) National University Corporation Kagawa University (JP) The Board of Trustees of the University of Arkansas (N/A)
Application Number:14/743,629
Patent Claims:1. A composition comprising: a collagen-binding polypeptide segment covalently linked to a PTH/PTHrP receptor antagonist; wherein the collagen-binding polypeptide segment is a ColH or ColG bacterial collagen binding polypeptide segment or a segment of a collagenase, wherein the PTH/PTHrP receptor antagonist comprises a peptide selected from the group consisting of residues 7-14 of SFQ ID NO: 7, residues 7-33 of SEQ ID NO: 7, residues 7-34 of SEQ ID NO: 7, residues 7-34 of SEQ ID NO: 8, and SEQ ID NO: 11, wherein the collagen-binding polypeptide segment comprises residues 38-158 of SEQ ID NO: 1, a fragment of at least 8 consecutive amino acids from residues 38-158 of SEQ ID NO: 1 or is at least 90% identical to residues 38-158 of SEQ ID NO: 1.

2. The composition of claim 1, wherein the collagen-binding polypeptide segment and the PTH/PTHrP receptor antagonist are chemically crosslinked to each other or are polypeptide portions of a fusion protein.

3. The composition of claim 1, wherein the PTH/PTHrP receptor antagonist is a polypeptide and the N-terminus of the collagen-binding polypeptide segment is linked directly or through a linker polypeptide segment to the C-terminus of the PTH/PTHrP receptor antagonist polypeptide.

4. The composition of claim 1, wherein the composition further comprises residues 37-130 of SEQ NO: 2 covalently linked to the collagen binding polypeptide segment.

5. The composition of claim 1, wherein the collagen binding polypeptide segment comprises residues 38-158 of SEQ ID NO 1.

6. The composition of claim 1, wherein the composition comprises SEQ NO: 10.

7. The composition of claim 1, wherein the PTH/PTHrP receptor antagonist consists of a polypeptide selected from the group consisting of residues 7-14 of SEQ ID NO 7, residues 7-33 of SEQ ID NO: 7, residues 7-34 of SEQ ID NO: 7 and residues 7-34 of SEQ ID NO: 8.

8. A method of promoting hair growth in a mammal comprising: administering the composition of claim 1 to the mammal in an amount effective to promote hair growth.

9. The method of claim 7, wherein the composition is administered locally at the site of desired hair growth.

10. The method of claim 7, wherein the administration is by subcutaneous or intradermal injection.

11. The method of claim 7, wherein the mammal is afflicted with chemotherapy-induced alopecia.

12. A method of treating or reducing renal osteodystrophy in a mammal comprising administering the composition of claim 1 to the mammal in an amount effective to reduce renal osteodystrophy or renal disease in the mammal.

13. The method of claim 12, wherein the composition is administered by injection.

14. A method of treating bone metastasis of cancer in a mammal comprising administering the composition of claim 1 to the mammal in an effective to reduce the incidence of bone metastasis of cancer or slow the growth of metastatic cancer in the bone in the mammal.

15. The method of claim 14, wherein the composition is administered by injection.

Details for Patent 9,528,099

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Advance Biofactures SANTYL collagenase VIAL 101995 001 1965-06-04 ➤ Sign Up Ochsner Clinic Foundation (N/A) National University Corporation Kagawa University (JP) The Board of Trustees of the University of Arkansas (N/A) 2027-04-09 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 9,528,099

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 2008124166 Jan 15, 2009
World Intellectual Property Organization (WIPO) 2008124166 Nov 05, 2009
World Intellectual Property Organization (WIPO) 2008124166 Oct 16, 2008
United States of America 10202434 Feb 12, 2019
United States of America 2010129341 May 27, 2010
United States of America 2013337017 Dec 19, 2013
>Country >Patent Number >Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Colorcon
Boehringer Ingelheim
AstraZeneca
Healthtrust
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.